BioLife Solutions (BLFS) announced that as part of a larger round of financing it has purchased $2M of convertible notes in Pluristyx, a Seattle based developer of innovative induced pluripotent stem cell, or iSPC, based products for cell therapy developers. BioLife also entered into a separate agreement which provides a board observer seat, and certain rights related to any potential future acquisition of Pluristyx.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BLFS: